Drug Trial Radar · NCT05653349
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
226
Actual
Start
Feb 3, 2023
Primary completion
Oct 29, 2026
Study completion Aug 11, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in increasing the rate of stable response off treatment at 12 months (SROT-12) in adult participants with primary ITP.
Conditions
- Primary Immune Thrombocytopenia (ITP)
Interventions
IanalumabBiological
Intravenous infusion, prepared from concentrate solution
PlaceboDrug
Intravenous infusion, prepared from matching placebo
CorticosteroidsDrug
Oral or parental (if clinically justified)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Stable Response off treatment at 12 months (SROT-12)Time frame: 12 months after last patient completed treatment
Locations
99 sites in 25 countries. Site status is shown where the registry gives one.
Yuma Regional Medical Center
Yuma, Arizona
Community Cancer Institute
Clovis, California
Compassionate Care Res Group Inc
Fountain Valley, California
University of Colorado Anschutz
Aurora, Colorado
DH Cancer Research Center LLC
Margate, Florida
Uni of Chi Medi Ctr Hema and Onco
Chicago, Illinois
Parkview Research Center
Fort Wayne, Indiana
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Med Center
Boston, Massachusetts
Mayo Clinic Rochester
Rochester, Minnesota
Hematology Oncology Association of Rockland
Nyack, New York
Rhode Island Hospital
Providence, Rhode Island
Mays Cancer Ctr Uthsa Mdacc
San Antonio, Texas
Community Cancer Trials of Utah
Ogden, Utah
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
San Miguel Tucuman, Tucumán Province, Argentina
Novartis Investigative Site
Garran, Australian Capital Territory, Australia
Novartis Investigative Site
Wooloongabba, Queensland, Australia
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Innsbruck, Tyrol, Austria
Novartis Investigative Site
Brasschaat, Belgium
Novartis Investigative Site
Bruges, Belgium
Novartis Investigative Site
Roeselare, West Vlaanderen, Belgium
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Bengbu, China
Novartis Investigative Site
Dalian, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Beijing, Beijing Municipality, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Shenzhen, Guangdong, China
Novartis Investigative Site
Shijiazhuang, Hebei, China
Novartis Investigative Site
Luoyang, Henan, China
Novartis Investigative Site
Zhengzhou, Henan, China
Novartis Investigative Site
Changzhou, Jiangsu, China
Novartis Investigative Site
Nanchang, Jiangxi, China
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.